NOTA Laboratories
Our mission is to commercialize single-use low-cost nitric oxide therapeutics that treat and prevent respiratory viral infections including COVID-19 and the flu
- Stage Product In Development
- Industry Medical Devices and Equipment
- Location Ann Arbor, MI, USA
- Currency USD
- Founded February 2015
- Employees 11
- Incorporation Type C-corp
- Website notalabs.com
Company Summary
NOTA Laboratories is a combination Device/Therapeutics company focused on low-cost delivery systems for inhaled nitric oxide (iNO). iNO is a proven virucide, bactericide, and vasodilator that is being used to treat COVID-19 and a broad array of other respiratory diseases, including the flu and COPD. NOTA's first product is a time-release chemical sachet that is placed into a face mask & used at the first sign of infection to reduce viral loading.
Team
-
Chief Executive OfficerMalcolm is a serial entrepreneur and has been CEO of several venture backed equipment and expendables companies over his long career. He has worked in the medical diagnostic analytical instrument, membrane filtration and water purification industries.
Mr. Kahn earned his BA at the Pennsylvania State University and MBA at Fordham. -
Prof. Mark MeyerhoffChief Technology OfficerDr. Meyerhoff is the Philip J. Erving Professor of Chemistry at the University of Michigan where he has taught and led his research laboratory for over 40 years. He is lead co-founder of NOTA Laboratories, having spent >20 years researching nitric oxide release materials and their potential medical applications. Dr. Meyerhoff has a proven track record in advancing inventions from his laboratory to industry through corporate partnerships.
-
Chief Financial Officer10+ years cross-functional experience in medical devices, including Corporate Finance, R&D Project Management, Healthcare Economics, and Global Product Management. Paul earned his BA at Brandeis University and MBA at University of Michigan.
-
Glenn MartinDirector of Research & DevelopmentDr. Martin is a creative and seasoned analytical chemist and technical leader. His industry experience includes Principal Research Scientist with Abbott's Point of Care diagnostic division (10 years), Chemistry Manager with Sensicore Inc. (7 years), and Founder and President of Selective Technologies Inc. (7 years). Dr. Martin holds a PhD in Analytical Chemistry from University of Delaware and a BS in Chemistry from University of Michigan
-
Danial DrakeMedical DirectorDaniel Drake, MD is a University of Michigan Medical School graduate and completed his general and trauma surgical residency at Parkland Memorial Hospital. He also completed a fellowship at UofM in cardiothoracic surgery. Dan was a founding member of the Munson Medical Center open-heart surgery program and president of the Mich Society of Thoracic & Cardiovascular Surgeons. He also founded and co-chaired the MSTCVS Quality Assurance Institute.
-
Joan KeiserDirector of Regulatory AffairsDr. Keiser is a biotechnology / pharmaceutical executive. She worked for 10 years as VP of Research for Pfizer. Prior to joining NOTA Laboratories, Dr. Keiser was Managing Director of the University of Michigan North Campus Research Complex. Dr. Keiser earned her PhD in Physiology from the University of Michigan, and her BS from Michigan State University.
Advisors
-
Dr. Mark ZacharekUnconfirmed -
Dr. Raimon Duran-StruuckUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.